Clinical Trial Update: Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer [Phase 1]

View source ↗

Summary

This Phase 1 study assesses the oral bioavailability of a new ABT-263 (navitoclax) formulation in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Malignancies
• Solid Tumors

Drugs mentioned

• ABT-263 (navitoclax)

Snippet

Sponsor: AbbVie | Conditions: Lymphoid Malignancy, Solid Tumors | Phase 1 | Status: COMPLETED